Jazz Pharmaceuticals and its partner PharmaMar, S.A. look likely to need another trial to support the full US approval of their novel anticancer Zepzelca in small-cell lung cancer after the Phase III ATLANTIS study missed its overall survival (OS) primary endpoint.
Zepzelca (lurbinectedin) received an accelerated approval from the US Food and Drug Administration in June for the treatment of adult...